
Atossa Genetics (ATOS) Stock Forecast & Price Target
Atossa Genetics (ATOS) Analyst Ratings
Bulls say
Atossa Therapeutics Inc. possesses a strong position in the oncology market, particularly due to the promising clinical trials of Z-endoxifen, which has demonstrated efficacy and safety across multiple indications in breast cancer, specifically showing numerically superior results compared to tamoxifen. The company’s strategic focus on metastatic breast cancer and the validation from interactions with regulatory consultants and key opinion leaders further enhances its prospects, positioning it favorably within a competitive landscape. Additionally, the potential for broader application of Z-endoxifen across various patient populations, combined with ongoing development of its COVID-19 therapeutics, underlines the company’s commitment to addressing high unmet medical needs, which may provide significant upside for stakeholders.
Bears say
Atossa Therapeutics Inc faces significant risks that contribute to a negative outlook on its stock, primarily related to safety and efficacy concerns surrounding its clinical and preclinical programs. The company anticipates needing approximately $275 million in additional financing through 2037 to maintain operations, with a cash runway projected only into the second half of 2026. Furthermore, potential regulatory challenges, intellectual property issues, and the risk of de-listing should the stock price fall below $1 exacerbate the financial uncertainties impacting investor confidence.
This aggregate rating is based on analysts' research of Atossa Genetics and is not a guaranteed prediction by Public.com or investment advice.
Atossa Genetics (ATOS) Analyst Forecast & Price Prediction
Start investing in Atossa Genetics (ATOS)
Order type
Buy in
Order amount
Est. shares
0 shares